MX350170B - Composición inmunogénica estable de antígenos de staphylococcus aureus. - Google Patents

Composición inmunogénica estable de antígenos de staphylococcus aureus.

Info

Publication number
MX350170B
MX350170B MX2013006960A MX2013006960A MX350170B MX 350170 B MX350170 B MX 350170B MX 2013006960 A MX2013006960 A MX 2013006960A MX 2013006960 A MX2013006960 A MX 2013006960A MX 350170 B MX350170 B MX 350170B
Authority
MX
Mexico
Prior art keywords
staphylococcus aureus
immunogenic compositions
aureus antigens
stable immunogenic
stable
Prior art date
Application number
MX2013006960A
Other languages
English (en)
Spanish (es)
Other versions
MX2013006960A (es
Inventor
Nema Sandeep
Khandke Lakshmi
Nonoyama Akihisa
Shafer Hodge Tamara
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2013006960A publication Critical patent/MX2013006960A/es
Publication of MX350170B publication Critical patent/MX350170B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
MX2013006960A 2010-12-22 2011-12-21 Composición inmunogénica estable de antígenos de staphylococcus aureus. MX350170B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061426476P 2010-12-22 2010-12-22
PCT/IB2011/055883 WO2012085872A2 (en) 2010-12-22 2011-12-21 Stable immunogenic compositions of staphylococcus aureus antigens

Publications (2)

Publication Number Publication Date
MX2013006960A MX2013006960A (es) 2013-07-15
MX350170B true MX350170B (es) 2017-08-28

Family

ID=45444677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006960A MX350170B (es) 2010-12-22 2011-12-21 Composición inmunogénica estable de antígenos de staphylococcus aureus.

Country Status (18)

Country Link
US (1) US20130259896A1 (enExample)
EP (2) EP3150222B1 (enExample)
JP (1) JP6097478B2 (enExample)
KR (2) KR101808398B1 (enExample)
CN (1) CN103826656B (enExample)
AU (1) AU2011346535B2 (enExample)
BR (1) BR112013016153A2 (enExample)
CA (1) CA2819120C (enExample)
DK (2) DK3150222T3 (enExample)
ES (2) ES2769425T3 (enExample)
HU (2) HUE033072T2 (enExample)
IL (1) IL226793B (enExample)
MX (1) MX350170B (enExample)
PL (2) PL3150222T3 (enExample)
PT (2) PT2654784T (enExample)
RU (1) RU2570730C2 (enExample)
SI (2) SI2654784T1 (enExample)
WO (1) WO2012085872A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
TWI505834B (zh) 2009-06-22 2015-11-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
EP3170508B1 (en) * 2010-06-04 2019-11-13 Wyeth LLC Vaccine formulations
CN103561762A (zh) * 2011-03-16 2014-02-05 明尼苏达大学董事会 诱导针对葡萄球菌属中细菌的免疫应答的组合物和方法
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
JP2016540764A (ja) * 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
AU2015245530B2 (en) * 2014-04-10 2019-10-03 Asit Biotech S.A. HSP-free allergen preparation
US20200360500A1 (en) * 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
JP2023512446A (ja) * 2020-01-13 2023-03-27 アプティーボ リサーチ アンド デベロップメント エルエルシー 治療的タンパク質の薬物送達システム構成要素への吸着を防ぐ方法および組成物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
EP1034277B1 (en) 1997-11-26 2012-06-27 Inhibitex, Inc. Extracellular matrix-binding proteins from Staphylococcus aureus
KR100644953B1 (ko) * 1998-08-31 2006-11-10 인히비텍스, 인코포레이티드 다성분 백신
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
CA2450939C (en) 2001-06-15 2012-11-06 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US9296795B2 (en) 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP2008513406A (ja) * 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
EP1998802A2 (en) * 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
AU2007317847B2 (en) * 2006-11-07 2013-10-31 Sanofi Pasteur Biologics, Llc Stabilization of vaccines by lyophilization
KR101695800B1 (ko) 2008-03-05 2017-02-22 사노피 파스퇴르 항원보강제 함유 백신 조성물의 안정화 방법
BRPI1015567A2 (pt) * 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus

Also Published As

Publication number Publication date
JP2012136518A (ja) 2012-07-19
KR101808398B1 (ko) 2017-12-12
DK3150222T3 (da) 2020-01-27
PL3150222T3 (pl) 2020-05-18
WO2012085872A2 (en) 2012-06-28
CA2819120A1 (en) 2012-06-28
HK1197370A1 (en) 2015-01-16
BR112013016153A2 (pt) 2017-07-11
PT3150222T (pt) 2020-02-03
CN103826656B (zh) 2015-08-26
AU2011346535A1 (en) 2013-06-13
ES2614815T3 (es) 2017-06-02
EP2654784A2 (en) 2013-10-30
CA2819120C (en) 2016-07-05
SI2654784T1 (sl) 2017-01-31
RU2570730C2 (ru) 2015-12-10
KR20130114210A (ko) 2013-10-16
RU2013128277A (ru) 2015-01-27
KR20150129071A (ko) 2015-11-18
WO2012085872A3 (en) 2012-08-30
US20130259896A1 (en) 2013-10-03
EP2654784B1 (en) 2016-12-07
IL226793B (en) 2019-02-28
EP3150222A1 (en) 2017-04-05
PT2654784T (pt) 2017-02-13
EP3150222B1 (en) 2019-11-27
DK2654784T3 (en) 2017-02-13
ES2769425T3 (es) 2020-06-25
JP6097478B2 (ja) 2017-03-15
SI3150222T1 (sl) 2020-02-28
HUE047263T2 (hu) 2020-04-28
CN103826656A (zh) 2014-05-28
HUE033072T2 (hu) 2017-11-28
MX2013006960A (es) 2013-07-15
AU2011346535B2 (en) 2015-09-24
PL2654784T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2013006960A (es) Composicion inmunogenica estable de antigenos de staphylococcus aureus.
ZA201903620B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2018243910A8 (en) A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
PE20142188A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
EP3470526A3 (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
NZ595689A (en) Compositions for immunising against staphylococcus aureus
MX2016009469A (es) Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
MX357202B (es) Composicion de particula tipo virus.
EP3536168A3 (en) Probiotic formulations and methods for use
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
WO2012033813A3 (en) Compositions for dyeing keratin fibers
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
AU2013331781A8 (en) Immunogenic composition comprising 1 or more Streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising Protein E and/or PilA from Haemophilus influenzae.
NZ741342A (en) Daptomycin formulations and uses thereof
MX2015002482A (es) Composicion inmunogenica.
SG11202007676RA (en) Immunogenic composition comprising staphylococcal antigens
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
MX2011012248A (es) Anticuerpos o sus fragmentos dirigidos contra un epitope de staphylococcus aureus de isaa o isab.
GB2568440A (en) Modified factor H binding protein
MY192792A (en) A composition of multivalent pneumococcal capsular polysaccharide-carrier protein conjugates and use thereof
WO2012031260A3 (en) Staphylococcus aureus specific human recombinant polyclonal antibodies and uses thereof
TW200716670A (en) Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
WO2013067160A3 (en) Anti-bacterial polypeptides and pathogen specific synthetic antibodies
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.
GB201114923D0 (en) Immunogenic proteins and compositions

Legal Events

Date Code Title Description
FG Grant or registration